TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Requirements After Cardiac Surgery: a Randomized Controlled Clinical Trial (TRACS STUDY)
Brief Summary: Blood transfusion is related to worse outcomes and the triggers for red blood cells transfusion are not well defined in cardiac surgery. Retrospective studies in cardiac surgery do not show benefits of red blood cell transfusion in reduction of morbidity and mortality in cardiac surgery. There are no prospective studies comparing outcomes between restrictive or liberal strategy in cardiac surgery.This study is a double-blind randomized study comparing clinical outcomes between two strategies of transfusion in cardiac surgery - liberal or restrictive.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid (Exacyl) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic acid (Exacyl); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Intervention Type: PROCEDURE; Name: red blood cell transfusion; Assigned to Arm(s): 1, 2
D: Arm Label: Liberal (10 g/dL) Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Liberal (10 g/dL) Transfusion Strategy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Restrictive (Symptomatic) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Liberal (10 g/dL) Transfusion Strategy; Assigned to Arm(s): Liberal (10 g/dL) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Restrictive (Symptomatic) Transfusion Strategy; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Requirements After Cardiac Surgery: a Randomized Controlled Clinical Trial (TRACS STUDY)
Brief Summary: Blood transfusion is related to worse outcomes and the triggers for red blood cells transfusion are not well defined in cardiac surgery. Retrospective studies in cardiac surgery do not show benefits of red blood cell transfusion in reduction of morbidity and mortality in cardiac surgery. There are no prospective studies comparing outcomes between restrictive or liberal strategy in cardiac surgery.This study is a double-blind randomized study comparing clinical outcomes between two strategies of transfusion in cardiac surgery - liberal or restrictive.


Options:
A: Arm Label: Restrictive Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive transfusion policy | Arm Label: Liberal Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal Transfusion Policy | Intervention Type: OTHER; Name: Restrictive transfusion policy; Assigned to Arm(s): Restrictive Transfusion Policy | Intervention Type: OTHER; Name: Liberal Transfusion Policy; Assigned to Arm(s): Liberal Transfusion Policy
B: Arm Label: Epo1 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo1 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Placebo and TT10; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Placebo and TT7; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: recombinant human erythropoietin, rhEpo; Assigned to Arm(s): Epo1 and TT10, Epo1 and TT7, Epo2 and TT10, Epo2 and TT7 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo and TT10, Placebo and TT7
C: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
D: Arm Label: Liberal Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive transfusion strategy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Requirements After Cardiac Surgery: a Randomized Controlled Clinical Trial (TRACS STUDY)
Brief Summary: Blood transfusion is related to worse outcomes and the triggers for red blood cells transfusion are not well defined in cardiac surgery. Retrospective studies in cardiac surgery do not show benefits of red blood cell transfusion in reduction of morbidity and mortality in cardiac surgery. There are no prospective studies comparing outcomes between restrictive or liberal strategy in cardiac surgery.This study is a double-blind randomized study comparing clinical outcomes between two strategies of transfusion in cardiac surgery - liberal or restrictive.


Options:
A: Arm Label: Single-Unit Blood Transfusion Protocol; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Transfusion | Arm Label: Multiple-Unit Blood Transfusion Protocol; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Transfusion | Intervention Type: BIOLOGICAL; Name: Blood Transfusion; Assigned to Arm(s): Multiple-Unit Blood Transfusion Protocol, Single-Unit Blood Transfusion Protocol
B: Arm Label: Restrictive; Type: ACTIVE_COMPARATOR; Interventions: Biological: Administration of Red Cell | Arm Label: Liberal; Type: ACTIVE_COMPARATOR; Interventions: Biological: Administration of Red Cell | Intervention Type: BIOLOGICAL; Name: Administration of Red Cell; Assigned to Arm(s): Liberal, Restrictive
C: Arm Label: Bair hugger forced air warming therapy; Type: EXPERIMENTAL; Interventions: Device: Bair Hugger forced air warming system | Arm Label: conventional warming care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bair Hugger forced air warming system; Assigned to Arm(s): Bair hugger forced air warming therapy
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Requirements After Cardiac Surgery: a Randomized Controlled Clinical Trial (TRACS STUDY)
Brief Summary: Blood transfusion is related to worse outcomes and the triggers for red blood cells transfusion are not well defined in cardiac surgery. Retrospective studies in cardiac surgery do not show benefits of red blood cell transfusion in reduction of morbidity and mortality in cardiac surgery. There are no prospective studies comparing outcomes between restrictive or liberal strategy in cardiac surgery.This study is a double-blind randomized study comparing clinical outcomes between two strategies of transfusion in cardiac surgery - liberal or restrictive.


Options:
A: Arm Label: Restrictive Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive transfusion policy | Arm Label: Liberal Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal Transfusion Policy | Intervention Type: OTHER; Name: Restrictive transfusion policy; Assigned to Arm(s): Restrictive Transfusion Policy | Intervention Type: OTHER; Name: Liberal Transfusion Policy; Assigned to Arm(s): Liberal Transfusion Policy
B: Arm Label: Low transfusion threshold; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: High transfusion threshold; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): High transfusion threshold, Low transfusion threshold
C: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial
Brief Summary: In nursing homes (NHs) 80% of the patients have dementia, between 60%-80% exhibit behavioural disturbances (BPSD), and more than 60% have pain. Both pain and BPSD is more common in those with severe dementia. Since older persons with dementia have less communicative skills, suffer from more pain and exhibit more agitation, pain may be a contributing factor in these patients. More than 40% of patients with BPSD are treated with neuroleptics despite described side-effects. There is an urgent need to investigate the impact of individual pain management on BPSD in patients with dementia.

It was hypothesized that

* pain increase BPSD in patients with dementia
* individual pain treatment decrease BPSD in patients with dementia


Options:
A: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Buprenorphine plaster; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine plaster | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Buprenorphine plaster; Assigned to Arm(s): Buprenorphine plaster | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin
B: Arm Label: Algorithm; Type: EXPERIMENTAL; Interventions: Behavioral: Algorithm | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Algorithm | Intervention Type: BEHAVIORAL; Name: Algorithm; Assigned to Arm(s): Algorithm, Control
C: Arm Label: Paracetamol or buprenorphine treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol, Drug: Buprenorphine | Arm Label: Paracetamol placebo or buprenorphine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paracetamol placebo, Drug: Buprenorphine placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Paracetamol or buprenorphine treatment | Intervention Type: DRUG; Name: Paracetamol placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo | Intervention Type: DRUG; Name: Buprenorphine placebo; Assigned to Arm(s): Paracetamol placebo or buprenorphine placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: TREA (Treatment Routes for Exploring Agitation) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Placebo Control Group | Intervention Type: BEHAVIORAL; Name: TREA (Treatment Routes for Exploring Agitation); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Placebo Control Group; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial
Brief Summary: In nursing homes (NHs) 80% of the patients have dementia, between 60%-80% exhibit behavioural disturbances (BPSD), and more than 60% have pain. Both pain and BPSD is more common in those with severe dementia. Since older persons with dementia have less communicative skills, suffer from more pain and exhibit more agitation, pain may be a contributing factor in these patients. More than 40% of patients with BPSD are treated with neuroleptics despite described side-effects. There is an urgent need to investigate the impact of individual pain management on BPSD in patients with dementia.

It was hypothesized that

* pain increase BPSD in patients with dementia
* individual pain treatment decrease BPSD in patients with dementia


Options:
A: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Buprenorphine plaster; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine plaster | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Buprenorphine plaster; Assigned to Arm(s): Buprenorphine plaster | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin
B: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: Citalopram and psychosocial intervention; Type: EXPERIMENTAL; Interventions: Drug: citalopram | Arm Label: Placebo and psychosocial intervention; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): Citalopram and psychosocial intervention | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo and psychosocial intervention
D: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients With Primary Insomnia
Brief Summary: This study will establish the safety and tolerability of suvorexant (MK-4305) when administered for up to 14 months. Participants will be randomized to receive suvorexant or placebo for a 12-month double-blind (DB) Treatment Phase. Participants who complete the 12-month DB Treatment Phase will enter a 2-month DB Randomized Discontinuation Phase. At the time of initial randomization, participants assigned to receive suvorexant during the initial 12-month Treatment Phase will be simultaneously randomized, in a 1:1 ratio, to receive either suvorexant or placebo during the 2-month Randomized Discontinuation Phase. Participants randomized to receive placebo in the initial 12-month Treatment Phase will continue to receive placebo during the 2-month Randomized Discontinuation Phase.

The first 3 nights of the Randomized Discontinuation Phase are referred to as the Run-Out Phase, and will assess rebound and withdrawal.


Options:
A: Arm Label: Suvorexant HD; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant High Dose (HD) | Arm Label: Suvorexant LD; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant Low Dose (LD) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Suvorexant High Dose (HD); Assigned to Arm(s): Suvorexant HD | Intervention Type: DRUG; Name: Suvorexant Low Dose (LD); Assigned to Arm(s): Suvorexant LD | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Melatonin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Melatonin 5 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Melatonin 5 mg; Assigned to Arm(s): Melatonin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant, Drug: Dose-matched Placebo to Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dose-matched Placebo to Suvorexant | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Dose-matched Placebo to Suvorexant; Assigned to Arm(s): Placebo, Suvorexant
D: Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Dietary Fructose on Glucose and Lipid Metabolism in Healthy Human Subjects
Brief Summary: The increasing intake of fructose has been associated with an increase in obesity among US children and adolescents, but its "dose dependent" effects on insulin sensitivity and lipid metabolism has not been studied in detail. Methods: 36 healthy male adult human subjects will be included in this study. They will be randomly allocated into a low, moderate or high fructose, a moderate or high glucose and a sucrose diet for 3 weeks. In randomized order and with 4 week wash out intervals each subject will receive all six different diets. Three day food records will be used to measure total fructose and glucose intake. During the low fructose diet subjects will be instructed to avoid nutrients containing fructose aiming at consumption of less than 1g fructose/d. During the moderate fructose diet subjects will receive 3x13.3g of fructose or glucose, respectively. High fructose diet subjects will receive either 3x26.7g/d of fructose, 3x 26.7g/d of glucose or 3x 26.7g/d of sucrose in the form of three daily soft drinks taken together with the three main meals.

75 g oral glucose tolerance testing will be performed and composite insulin sensitivity index will be calculated The presence of phosphorylated fructose metabolites in plasma will be measured by targeted LC-MS/MS. In addition, metabolite biomarkers in plasma will be screened by untargeted metabolite profiling using both LC-MS and GC-MS. In a subgroup of 10 subjects an euglycemic hyperinsulinemic clamp will be performed using \[6,6- 2H2\]glucose.

Thus, the lipogenic potential of fructose in humans will be compared with isocaloric amounts of glucose. Particularly, the question whether lipogenic effects are continuously dose dependent or whether there is a lipogenic shunting and if yes, at what level of ingested fructose will be addressed.


Options:
A: Arm Label: Crispbread; Type: EXPERIMENTAL; Interventions: Behavioral: Crispbread | Arm Label: Liquid meal replacement; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Crispbread | Intervention Type: BEHAVIORAL; Name: Crispbread; Assigned to Arm(s): Crispbread, Liquid meal replacement
B: Intervention Type: OTHER; Name: Fructose; Assigned to Arm(s): N/A
C: Intervention Type: OTHER; Name: Dietary fructose; Assigned to Arm(s): N/A
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: artificially sweetened beverages | Intervention Type: DIETARY_SUPPLEMENT; Name: artificially sweetened beverages; Assigned to Arm(s): intervention group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Prevention Trial Substituting Brown Rice for White Rice to Lower Markers for Diabetes Risk
Brief Summary: The specific aim of this study is to determine the effects of substituting brown for white rice on the treatment of metabolic syndrome (MetS).


Options:
A: Arm Label: Refined grain; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Refined grain | Arm Label: Whole grain diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Whole grain diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Whole grain diet; Assigned to Arm(s): Whole grain diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Refined grain; Assigned to Arm(s): Refined grain
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Brown rice/White rice | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Brown rice/White rice | Intervention Type: DIETARY_SUPPLEMENT; Name: Brown rice/White rice; Assigned to Arm(s): A, B
C: Intervention Type: BEHAVIORAL; Name: Whole Grain Foods; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Diet with increased intake of rye bread, berries and fish | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Increased intake of whole grain and rye bread | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control diet with decreased intake of rye bread, berries and fish | Intervention Type: DIETARY_SUPPLEMENT; Name: Diet with increased intake of rye bread, berries and fish; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: Increased intake of whole grain and rye bread; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Control diet with decreased intake of rye bread, berries and fish; Assigned to Arm(s): C

Answer: B